Lakeside Holding LTD 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Lakeside Holding Limited reported a significant increase in revenue for its pharmaceutical distribution business in Q1 2026, driven by expanded customer base and sales of infusion products, despite a decrease in gross profit margin.
NASDAQ
Lakeside Holding Limited reported a 49.5% increase in total revenue for Q1 2025, driven by strong airfreight demand and a new pharmaceutical distribution segment, despite a continued net loss.
NASDAQ
Lakeside Holding Limited's Q3 2025 results reveal a revenue decrease due to lower freight volumes, partially offset by new pharmaceutical distribution revenue, alongside increased operating expenses.
NASDAQ
10-Q: Lakeside Holding Limited Reports Disappointing Q2 Results Amid Revenue Decline and Rising Expenses
Lakeside Holding Limited's Q2 results reveal a net loss of $1.9 million, a stark contrast to the previous year's income, driven by decreased revenues and increased operating expenses.
NASDAQ
Lakeside Holding Limited's first quarter 2025 results show a slight decrease in revenue, but a strategic shift towards Asia-based customers and a recent acquisition in China signal future growth.